ATE254136T1 - Interaktions-fullensysteme zum nachweis von protein-interaktionen - Google Patents
Interaktions-fullensysteme zum nachweis von protein-interaktionenInfo
- Publication number
- ATE254136T1 ATE254136T1 AT95928118T AT95928118T ATE254136T1 AT E254136 T1 ATE254136 T1 AT E254136T1 AT 95928118 T AT95928118 T AT 95928118T AT 95928118 T AT95928118 T AT 95928118T AT E254136 T1 ATE254136 T1 AT E254136T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- binding
- interaction
- gene
- protein interactions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Vehicle Body Suspensions (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27808294A | 1994-07-20 | 1994-07-20 | |
| PCT/US1995/009307 WO1996002561A1 (en) | 1994-07-20 | 1995-07-20 | Interaction trap systems for detecting protein interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE254136T1 true ATE254136T1 (de) | 2003-11-15 |
Family
ID=23063609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95928118T ATE254136T1 (de) | 1994-07-20 | 1995-07-20 | Interaktions-fullensysteme zum nachweis von protein-interaktionen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6004746A (de) |
| EP (2) | EP0773952B1 (de) |
| JP (1) | JP4064452B2 (de) |
| AT (1) | ATE254136T1 (de) |
| DE (1) | DE69532127T2 (de) |
| DK (1) | DK0773952T3 (de) |
| ES (1) | ES2210306T3 (de) |
| HK (1) | HK1012006A1 (de) |
| WO (1) | WO1996002561A1 (de) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE254136T1 (de) * | 1994-07-20 | 2003-11-15 | Gen Hospital Corp | Interaktions-fullensysteme zum nachweis von protein-interaktionen |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| CA2252886C (en) * | 1996-04-26 | 2008-02-12 | Massachusetts Institute Of Technology | Three-hybrid screening assay |
| DE29724617U1 (de) * | 1996-04-26 | 2002-06-13 | Massachusetts Institute Of Technology, Cambridge, Mass. | Drei-Hybrid-Kit zur Molekülauswahl |
| US5776689A (en) * | 1996-07-19 | 1998-07-07 | The Regents Of The University Of California | Protein recruitment system |
| US5807708A (en) * | 1996-07-30 | 1998-09-15 | Millennium Pharmaceuticals, Inc. | Conservin nucleic acid molecules and compositions |
| US5846722A (en) * | 1996-10-16 | 1998-12-08 | Terrapin Technologies, Inc. | System to detect small molecule/peptide interaction |
| WO1998046796A1 (en) * | 1997-04-11 | 1998-10-22 | The Regents Of The University Of California | A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways |
| AU3587599A (en) * | 1997-11-28 | 1999-06-16 | Invitrogen Corporation | Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo |
| EP1035207A1 (de) * | 1999-03-09 | 2000-09-13 | MultiGene Biotech GmbH | cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie |
| EP1792989A1 (de) | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird |
| JP2002541800A (ja) | 1999-04-12 | 2002-12-10 | アジェンシス， インコーポレイテッド | 前立腺癌において発現される１３回膜貫通タンパク質 |
| CA2377573A1 (en) * | 1999-06-26 | 2001-01-04 | Joelle Nina Pelletier | An in vivo library-versus-library selection of optimized protein-protein interactions |
| EP1200590B1 (de) | 1999-08-12 | 2009-01-07 | Agensys, Inc. | C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen |
| ES2316387T3 (es) | 1999-10-05 | 2009-04-16 | Agensys, Inc. | Receptor acoplado a proteina g sobrexpresado en cancer de prostata y la utilizacion del mismo. |
| US6893818B1 (en) * | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
| US20030211495A1 (en) * | 2000-03-08 | 2003-11-13 | Richard Hopkins | Reverse n-hybrid screening method |
| CA2415923C (en) | 2000-07-12 | 2011-10-25 | Agensys, Inc. | Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| PT1313850E (pt) | 2000-08-28 | 2008-11-18 | Agensys Inc | Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro |
| ATE447965T1 (de) * | 2000-09-11 | 2009-11-15 | Dana Farber Cancer Inst Inc | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren |
| EP1330544A4 (de) | 2000-09-26 | 2005-04-06 | Univ Duke | Rna-aptamere und verfahren zu deren identifizierung |
| JP4276432B2 (ja) * | 2000-12-22 | 2009-06-10 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｍｕｃ１による細胞増殖調節方法 |
| WO2002051438A2 (en) | 2000-12-22 | 2002-07-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (rgm) and its modulators |
| JP4343534B2 (ja) | 2001-03-02 | 2009-10-14 | ゲーペーツェー バイオテック アクチェンゲゼルシャフト | ３ハイブリッド・アッセイ・システム |
| US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| EP2280030A3 (de) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Nukleinsäuren und zugehörige Proteine für die Behandlung und den Nachweis von Krebs |
| DK1401853T3 (da) * | 2001-05-25 | 2010-11-01 | Univ Duke | Modulatorer af farmakologiske midler |
| EP1429793B1 (de) | 2001-09-06 | 2015-02-25 | Agensys, Inc. | Nucleinsäure und entsprechendes protein, steap-1, bei der behandlung und zum nachweis von krebs |
| US20040049024A1 (en) * | 2001-12-07 | 2004-03-11 | Geoff Clark | Compositions and methods related to the minn1 tumor suppressor gene and protein |
| US20040086945A1 (en) * | 2002-06-03 | 2004-05-06 | The Procter & Gamble Company | Hairless protein-interacting partner complexes and methods thereto |
| CA2542171C (en) * | 2002-06-26 | 2015-12-15 | Abbott Gmbh & Co. Kg | Modulators and modulation of the interaction between rgm and neogenin |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| US20060099713A1 (en) * | 2002-10-01 | 2006-05-11 | Buck Institute | Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires |
| CA2860151A1 (en) | 2003-02-10 | 2004-08-26 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| WO2004092339A2 (en) * | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
| JP2007525196A (ja) | 2003-05-30 | 2007-09-06 | アジェンシス， インコーポレイテッド | 前立腺幹細胞抗原（ｐｓｃａ）変異体及びその部分配列 |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| DE602004020855D1 (de) | 2003-11-20 | 2009-06-10 | Hoffmann La Roche | Spezifische Marker für Stoffwechselssyndrome |
| US20070202134A1 (en) * | 2004-02-23 | 2007-08-30 | Kufe Donald W | Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis |
| AU2005238490B2 (en) | 2004-04-22 | 2010-11-18 | Tobira Therapeutics, Inc. | Improved modulators of coagulation factors |
| PL1753871T3 (pl) | 2004-05-28 | 2016-01-29 | Agensys Inc | Przeciwciała i powiązane cząsteczki, które wiążą się z antygenem komórek macierzystych prostaty (PSCA) |
| US8034553B2 (en) | 2004-06-24 | 2011-10-11 | Kimberly-Clark Worldwide, Inc. | Biomarkers for wound healing |
| AU2006230563B8 (en) | 2005-03-31 | 2010-06-17 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
| WO2007039256A2 (de) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
| EP2080029B1 (de) | 2006-08-31 | 2014-03-26 | Nexigen GmbH | Mittel und verfahren zum nachweis von protein-peptid-wechselwirkungen |
| EP1927364A1 (de) * | 2006-12-01 | 2008-06-04 | Ecole Normale Superieure De Lyon | Polypetitde mit modulatorischer Wirkung auf Zellen |
| WO2008097844A2 (en) * | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| EP2034020A1 (de) * | 2007-08-30 | 2009-03-11 | Procomcure Biotech GmbH | Verfahren zur Herstellung eines modifizierten Peptids |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| EP2101173A1 (de) * | 2008-03-14 | 2009-09-16 | Vivalis | In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist |
| CN102027561A (zh) * | 2008-05-15 | 2011-04-20 | 皇家飞利浦电子股份有限公司 | 生成x射线束的方法和系统 |
| US8796415B2 (en) | 2009-10-22 | 2014-08-05 | Centre National De La Recherche Scientifique | Inhibitors of guanine exchange factors and their use as anticancer drugs |
| MX2012006560A (es) | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| WO2011083147A1 (en) | 2010-01-08 | 2011-07-14 | Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh | Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen |
| EP2561068A1 (de) | 2010-04-19 | 2013-02-27 | Medizinische Universität Innsbruck | Für tetrahydrobiopterin-abhängige alkylglycerolmonooxygenaseaktivität kodierende tmem195 |
| SG10201600316SA (en) | 2012-01-27 | 2016-02-26 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| MX2017008487A (es) | 2014-12-24 | 2018-02-19 | Neximmune Inc | Composiciones de nanoparticulas y metodos para inmunoterapia. |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| KR20180081608A (ko) | 2015-11-19 | 2018-07-16 | 아스클리픽스 테라퓨틱스, 엘엘씨. | 항-혈관형성, 항-림프관신생, 및 항-부종성 특성을 가진 펩티드 및 나노입자 제제 |
| CN109071627B (zh) | 2016-02-05 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | Cd8结合剂 |
| EP3426278B1 (de) | 2016-03-07 | 2024-01-03 | Vib Vzw | Einzeldomänenantikörper gegen cd20 |
| WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
| EP3454887B1 (de) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Zielgerichtete mutanten-interferon-beta und verwendungen davon |
| US20190225670A1 (en) | 2016-10-04 | 2019-07-25 | Asclepix Therapeutics, Llc | Compounds and methods for activating tie2 signaling |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| WO2019028427A1 (en) | 2017-08-03 | 2019-02-07 | Asclepix Therapeutics, Llc. | METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR |
| WO2019075056A1 (en) | 2017-10-10 | 2019-04-18 | The Johns Hopkins University | BIODEGRADABLE BIOMIMETIC PARTICLES |
| WO2019099678A1 (en) * | 2017-11-16 | 2019-05-23 | Synthex, Inc. | Selective modulation of protein-protein interactions |
| JP2021513361A (ja) | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| EP3924379A4 (de) | 2019-02-15 | 2022-12-21 | Integral Molecular, Inc. | Antikörper mit einer gemeinsamen leichten kette und deren verwendungen |
| EP3924389A4 (de) | 2019-02-15 | 2023-06-14 | Integral Molecular, Inc. | Claudin-6-antikörper und deren verwendungen |
| WO2020232343A1 (en) | 2019-05-15 | 2020-11-19 | Synthex, Inc. | Selective degradation of proteins |
| EP4069731A4 (de) | 2019-12-03 | 2024-05-29 | Alamar Biosciences, Inc. | Nukleinsäure-gekoppelter immun-sandwich-assay (nulisa) |
| GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
| WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
| WO2024077118A2 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2024118771A1 (en) | 2022-11-30 | 2024-06-06 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| WO2024208816A1 (en) | 2023-04-03 | 2024-10-10 | Vib Vzw | Blood-brain barrier crossing antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
| US4980281A (en) * | 1988-02-10 | 1990-12-25 | Housey Gerard M | Method of screening for protein inhibitors and activators |
| US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| EP0496162A3 (en) * | 1990-12-24 | 1993-09-01 | Merck & Co. Inc. | Peptide inhibitors of ras-gap interaction |
| US5270181A (en) * | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| US5885780A (en) * | 1991-07-19 | 1999-03-23 | University Of Utah | Method of obtaining small conformationally rigid conopeptides |
| US5352660A (en) * | 1991-10-31 | 1994-10-04 | Mount Sinai Hospital Corporation | Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system |
| EP0672131B1 (de) * | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | Ein neues zellzyklus kontrollprotein |
| US5695941A (en) * | 1994-06-22 | 1997-12-09 | The General Hospital Corporation | Interaction trap systems for analysis of protein networks |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| ATE254136T1 (de) * | 1994-07-20 | 2003-11-15 | Gen Hospital Corp | Interaktions-fullensysteme zum nachweis von protein-interaktionen |
| US6365344B1 (en) * | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| US6455247B1 (en) * | 1996-01-23 | 2002-09-24 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| US6114111A (en) * | 1998-03-30 | 2000-09-05 | Rigel Pharmaceuticals, Inc. | Mammalian protein interaction cloning system |
-
1995
- 1995-07-20 AT AT95928118T patent/ATE254136T1/de active
- 1995-07-20 ES ES95928118T patent/ES2210306T3/es not_active Expired - Lifetime
- 1995-07-20 EP EP95928118A patent/EP0773952B1/de not_active Expired - Lifetime
- 1995-07-20 US US08/504,538 patent/US6004746A/en not_active Expired - Lifetime
- 1995-07-20 DK DK95928118T patent/DK0773952T3/da active
- 1995-07-20 JP JP50527796A patent/JP4064452B2/ja not_active Expired - Fee Related
- 1995-07-20 EP EP03021647A patent/EP1405911A1/de not_active Withdrawn
- 1995-07-20 WO PCT/US1995/009307 patent/WO1996002561A1/en active IP Right Grant
- 1995-07-20 DE DE69532127T patent/DE69532127T2/de not_active Expired - Lifetime
-
1998
- 1998-12-11 HK HK98113236A patent/HK1012006A1/xx not_active IP Right Cessation
-
1999
- 1999-02-12 US US09/249,458 patent/US6242183B1/en not_active Expired - Lifetime
-
2008
- 2008-03-26 US US12/079,358 patent/US20090130676A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6004746A (en) | 1999-12-21 |
| EP0773952A4 (de) | 2000-01-19 |
| JP4064452B2 (ja) | 2008-03-19 |
| ES2210306T3 (es) | 2004-07-01 |
| DE69532127D1 (de) | 2003-12-18 |
| US20090130676A1 (en) | 2009-05-21 |
| EP1405911A1 (de) | 2004-04-07 |
| EP0773952A1 (de) | 1997-05-21 |
| JPH10504713A (ja) | 1998-05-12 |
| WO1996002561A1 (en) | 1996-02-01 |
| EP0773952B1 (de) | 2003-11-12 |
| US6242183B1 (en) | 2001-06-05 |
| DE69532127T2 (de) | 2004-08-26 |
| HK1012006A1 (en) | 1999-07-23 |
| DK0773952T3 (da) | 2004-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE254136T1 (de) | Interaktions-fullensysteme zum nachweis von protein-interaktionen | |
| DK0765389T3 (da) | Cellesystemer havende specifik interaktion på peptide bindingspar | |
| ATE393228T1 (de) | Fusionsproteine und deren verwendung zur messung von protease-aktivität | |
| ATE253645T1 (de) | Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien | |
| DE19781162T1 (de) | Synchronisiertes Analyt-Testsystem | |
| CA2148252A1 (en) | Interaction trap system for isolating novel proteins | |
| DE60118527D1 (de) | Sensible und multiplexe diagnostische tests zur proteinanalyse | |
| DE69607176D1 (de) | Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper | |
| DE69734204D1 (de) | Lichtproduzierender biosensor | |
| EP1403640A4 (de) | Peptidimmobilisierte grundplatte und vefahren zum testen eines zielproteins unter verwendung derselben | |
| NO962084L (no) | DNA sekvens som koder for en BMP reseptor | |
| AU2002229974A1 (en) | Biochemical method and apparatus for detecting protein characteristics | |
| WO2002050104A3 (en) | Methods and cells for detecting modulators of rgs proteins | |
| DE59914900D1 (de) | Methode zur zellulären high-throughput-detektion von rezeptor-liganden-interaktionen | |
| DE59914992D1 (de) | Methode zur zellulären high-throughput-detektion von nukleären rezeptor-liganden-interaktionen | |
| JPS59141054A (ja) | 電気泳動装置 | |
| ATE307893T1 (de) | Verfahren zum nachweis von biologisch aktiven substanzen | |
| Durkee | Development of amplified detection systems for protein blotting using a solid phase coagulation assay. | |
| Rand | Blotting Techniques for the Detection of Protein Polymorphisms in Stains | |
| HUP0303646A2 (hu) | ABCG2-féltranszporter fehérje expresszióján alapuló szkrínelő rendszer | |
| NZ513455A (en) | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0773952 Country of ref document: EP |